Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
MALVERN, Pa., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced enhancements to its NeuroStar Advanced Therapy and proprietary TrakStar® patient data management software, introducing a range of new features aimed at improving patient communication, streamlining clinical data capture, and strengthening cybersecurity.
“With the latest upgrades, we’re not just enhancing technology; we’re transforming the way practices can care for patients,” said Cory Anderson, SVP of R&D and Clinical. “The new features in the NeuroStar System and TrakStar are designed to empower providers with the tools they need to deliver more personalized, efficient, and secure treatment. Our commitment is to continually push the boundaries of what our technology can do, ensuring that NeuroStar remains at the forefront of advancing the way patients receive treatment in their battle against depression.”
The software updates provide practices with more robust tools to enhance patient care and streamline operations for NeuroStar practices. Key upgrades include:
TrakStar software updates are available today for all cloud-based NeuroStar providers. NeuroStar System software updates are being delivered in a phased rollout throughout the year. For more information about NeuroStar TMS Therapy, please visit www.neurostar.com.
AboutNeuroneticsNeuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.6 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, visit www.neurostar.com.
Media Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
Reporter Name | Cascella Robert |
Relationship | Director |
Type | Purchase |
Amount | $75,000 |
SEC Filing | Form 4 |
Robert Cascella, serving as a Director at Neuronetics, has purchased 100,000 shares of the company's common stock at a price of $0.75 per share, totaling a purchase amount of $75,000. Following this transaction, Cascella directly owns 453,098 shares of Neuronetics.
SEC Filing: Neuronetics, Inc. [ STIM ] - Form 4 - Sep. 13, 2024
BALA CYNWYD, Pa., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Enstar Group Limited (Nasdaq – ESGR)
Under the terms of the agreement, Enstar will be acquired by Sixth Street for $338.00 in cash per ordinary share of Enstar payable upon closing of the transaction, representing a total equity value of $5.1 billion. The investigation concerns whether Enstar Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Sixth Street is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/enstar-group-limited-nasdaq-esgr/
PetIQ, Inc. (Nasdaq – PETQ)
Under the terms of the Merger Agreement, PetIQ will be acquired by Bansk Group (“Bansk”) in a deal valued at approximately $1.5 billion. Bansk will acquire all outstanding shares of PetIQ for $31.00 in cash. The investigation concerns whether the PetIQ Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Bansk is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/petiq-inc-nasdaq-petq/.
Greenbrook TMS, Inc. (OTC – GBNHF)
Under the terms of the agreement, Greenbrook TMS will be acquired by Neuronetics, Inc. (“Neuronetics”) (Nasdaq – STIM) in an all-stock transaction. Each Greenbrook share is expected to be exchanged for 0.01149 shares of Neuronetics common stock at the closing of the transaction. Following the closing of the transaction, Neuronetics shareholders will own approximately 57% of the combined company, and Greenbrook shareholders will own approximately 43% of the combined company, respectively, on a fully diluted basis. The investigation concerns whether the Greenbrook TMS Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Neuronetics is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/greenbrook-tms-inc-otc-gbnhf/.
GSE Solutions, Inc. (Nasdaq – GVP)
Under the terms of the agreement, GSE Solutions will be acquired by Pelican Energy Partners (“Pelican”) for $4.10 in cash. The investigation concerns whether the GSE Solutions Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Pelican is paying fair value to shareholders of the Company. For example, the deal consideration is below the 52-week high of $5.38 for the Company’s shares.
Additional information can be found at https://www.brodskysmith.com/cases/gse-solutions-inc-nasdaq-gvp/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
MALVERN, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is proud to shine a light on the powerful stories shared through the NeuroStar Voices Portal in recognition of Suicide Prevention Month. Launched last year, the portal has become a vital platform for individuals to share their journeys of battling depression and reclaiming their lives through NeuroStar Advanced Therapy.
NeuroStar is also marking a key milestone, reaching halfway toward its goal of saving 3,325 lives with this transformative therapy. In less than three years, NeuroStar has treated 88,533 patients, potentially saving 1,771 lives. This achievement is part of a five-year plan to treat 166,240 people with NeuroStar TMS and save 3,325 lives.*1 The five-year plan accelerates momentum gained since NeuroStar’s initial FDA clearance in 2008. The 88,533 patients treated in such a short time represent more than half the total number of patients treated between 2008 and 2023.
“When we set the goal of saving 3,325 lives, it was more than an objective—it was a heartfelt commitment to providing hope to those struggling to stay afloat,” said Keith J. Sullivan, President and CEO of Neuronetics, Inc. “Surpassing the halfway mark underscores that every life saved is a testament the bravery of those fighting depression and the impact NeuroStar has on their mental health journey. The inspiring stories shared through the NeuroStar Voices Portal humanizes these milestones, showcasing the transformative power of our therapy and the renewed hope it brings to individuals and their families.”
The NeuroStar Voices Portal powerfully illustrates NeuroStar’s life-saving impact on those battling depression, as well as its profound effects on families and communities.
According to the Centers for Disease Control and Prevention, suicide deaths reached a record high in 2022, with nearly 50,000 Americans losing their lives to suicide, reflecting an urgent and ongoing need for effective mental health treatments.2 These findings highlight the critical importance of continued innovation and commitment in mental health care and underscore how NeuroStar plays a vital role in providing support and hope to those in need. For more information about NeuroStar TMS Therapy, please visit www.neurostar.com.
*Based on a suicide rate of 2%.
AboutNeuroneticsNeuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.6 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, visit www.neurostar.com.
Media Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
Sources
Reporter Name | Muir Glenn P |
Relationship | Director |
Type | Purchase |
Amount | $21,250 |
SEC Filing | Form 4 |
Glenn P Muir, serving as a Director at Neuronetics, has purchased a total of 25,000 shares of Common Stock on August 28 and 29, 2024, at a price of $0.85 per share, amounting to a total purchase of $21,250. Following these transactions, Muir directly owns 264,818 shares of Neuronetics.
SEC Filing: Neuronetics, Inc. [ STIM ] - Form 4 - Aug. 30, 2024
Reporter Name | Muir Glenn P |
Relationship | Director |
Type | Purchase |
Amount | $25,000 |
SEC Filing | Form 4 |
Glenn P Muir, serving as a Director at Neuronetics, purchased 25,000 shares of the company's common stock on August 20, 2024, at a price of $1.0 per share, totaling a $25,000 investment. Following this transaction, Muir directly owns 239,818 shares of Neuronetics.
SEC Filing: Neuronetics, Inc. [ STIM ] - Form 4 - Aug. 21, 2024
MALVERN, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, proudly announces the two-year anniversary of NeuroStar University (NSU). This milestone will be celebrated with a special event held at the NSU training center in Charlotte, North Carolina, showcasing the profound impact of NSU's pioneering training programs on pioneering new standards in patient care and responsiveness.
"NeuroStar University is a key part of our ongoing commitment to supporting our healthcare providers. The skills they gain through this training directly enhance the care they deliver with NeuroStar's innovative therapy, making a real impact in the lives of people with treatment-resistant depression," said Keith J. Sullivan, President and CEO of Neuronetics, Inc. "We're especially grateful for Martha's presence here today and her exceptional dedication and support to help tell the stories of people who have overcome depression. We look forward to building on the success of NSU for many years to come.”
The celebration will commence Tuesday, August 20, with a private book signing and meet-and-greet event featuring award-winning patient advocate Martha Rhodes, author of the book 3,000 Pulses Later. The following day, NSU will host a day of classes that begins with a featured fireside chat and Q&A between Martha Rhodes and NeuroStar CEO Keith Sullivan. This discussion will showcase the vital role NSU plays in elevating clinical training and enhancing the patient experience.
“I’m thrilled to be part of NeuroStar’s journey and to see the difference they’re making in mental health care,” said Martha Rhodes. “NeuroStar University’s commitment to cutting-edge education and patient support is remarkable, and I’m eager to share my experiences and contribute to this important dialogue.”
Over the past two years, NSU has become a beacon of excellence for healthcare professionals seeking advanced TMS education, having trained over 678 NeuroStar providers. As the only program of its kind in the neurobehavioral space, NSU offers practices an unparalleled opportunity to analyze, enhance, and elevate their NeuroStar business through advanced clinical trainings and practice development. As a result, these attendees treat an average of 61% more patients compared to non-attendee counterparts, ensuring that more individuals in need receive potentially life-changing therapy.
For more information about NeuroStar TMS Therapy, please visit www.neurostar.com.
AboutNeuroneticsNeuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.6 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, visit www.neurostar.com.
Media Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.